<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36737098</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000850</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000850</ELocationID><Abstract><AbstractText Label="BACKGROUND">The short-term and long-term outcome of inflammatory neuropsychiatric SLE (NPSLE) with immunosuppressive treatment is largely unknown. We used clinical data from our tertiary referral centre for NPSLE to investigate the type of inflammatory NPSLE manifestations, type of immunosuppressive treatment prescribed for these manifestations and clinical outcomes.</AbstractText><AbstractText Label="METHODS">All patients with SLE visiting the Leiden University Medical Centre NPSLE clinic between 2007 and 2021 receiving immunosuppressive therapy for neuropsychiatric symptoms were included. Clinical, immunological and radiological information was collected in as standardised way during a 1-day multidisciplinary assessment. In a multidisciplinary consensus meeting, the presence of NPSLE and the type of NPSLE manifestations and treatment were determined. For this study, short-term (0-6 months) and long-term outcomes (7-24 months) of the NP symptoms were assessed by two independent readers and scored on a 7-point Likert scale, ranging from death to resolved.</AbstractText><AbstractText Label="RESULTS">In total, 95 out of 398 (24%) patients visiting the NPSLE clinic between 2007 and 2021 received any form of immunosuppressive treatment for 101 separate NPSLE events. The most common NP manifestation was cognitive dysfunction (50%) as identified by formal cognitive assessment, often present in combination with other NPSLE manifestations. Treatment modalities were induction (24%), induction and maintenance (73%) and other therapy (3%). The treatments mostly consisted of (combinations of) prednisone (97%), methylprednisolone (53%), azathioprine (generally 2 mg/kg daily) (49%) and cyclophosphamide (generally induction 750 mg/m<sup>2</sup> every 4 weeks for 24 weeks or 500mg biweekly for 12 weeks) (42%). Short-term outcome showed improvement on the Likert scale in 73% (improved: 22%, much improved: 29%, resolved: 22%), no change in 21% and worsening in 6% of patients. Long-term outcome was available for 78 out of 101 events and showed improvement in 70% (improved: 14%, much improved: 28%, resolved: 28%), no change in 17%, worsening in 10% and death in 3% of patients (none directly NPSLE-related).</AbstractText><AbstractText Label="CONCLUSION">The outcome of inflammatory NPSLE after immunosuppressive treatment is generally good, with improvement of neuropsychiatric symptoms occuring in approximately 70% of events.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Monahan</LastName><ForeName>Rory C</ForeName><Initials>RC</Initials><Identifier Source="ORCID">0000-0003-2561-7085</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands R.C.Monahan@lumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beaart-van de Voorde</LastName><ForeName>Liesbeth J J</ForeName><Initials>LJJ</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fronczek</LastName><ForeName>Rolf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, LUMC, Leiden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SEIN, Hoofddorp, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Bresser</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, LUMC, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eikenboom</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Thrombosis and Hemostasis, LUMC, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kloppenburg</LastName><ForeName>Margreet</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9294-2307</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Middelkoop</LastName><ForeName>Huub A M</ForeName><Initials>HAM</Initials><AffiliationInfo><Affiliation>Department of Neurology, LUMC, Leiden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psychology, Health, Medical and Neuropsychology Unit, Leiden University, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terwindt</LastName><ForeName>Gisela M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Neurology, LUMC, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Wee</LastName><ForeName>Nic J A</ForeName><Initials>NJA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, LUMC, Leiden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Brain and Cognition, Leiden University, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huizinga</LastName><ForeName>Tom W J</ForeName><Initials>TWJ</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steup-Beekman</LastName><ForeName>Gerda M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Haaglanden Medical Centre, the Hague, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020945" MajorTopicYN="Y">Lupus Vasculitis, Central Nervous System</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">lupus erythematosus, systemic</Keyword><Keyword MajorTopicYN="N">outcome assessment, healthcare</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>20</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36737098</ArticleId><ArticleId IdType="pmc">PMC9900068</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000850</ArticleId><ArticleId IdType="pii">10/1/e000850</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bertsias G, Ioannidis JPA, Boletis J, et al. . EULAR recommendations for the management of systemic lupus erythematosus. report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis 2008;67:195&#x2013;205. 10.1136/ard.2007.070367</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2007.070367</ArticleId><ArticleId IdType="pubmed">17504841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol 2010;6:358&#x2013;67. 10.1038/nrrheum.2010.62</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2010.62</ArticleId><ArticleId IdType="pubmed">20458332</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias GK, Ioannidis JPA, Aringer M, et al. . EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing Committee for clinical Affairs. Ann Rheum Dis 2010;69:2074&#x2013;82. 10.1136/ard.2010.130476</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.130476</ArticleId><ArticleId IdType="pubmed">20724309</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust 2009;190:S54&#x2013;60. 10.5694/j.1326-5377.2009.tb02471.x</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/j.1326-5377.2009.tb02471.x</ArticleId><ArticleId IdType="pubmed">19351294</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanly JG, Urowitz MB, Su L, et al. . Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010;69:529&#x2013;35. 10.1136/ard.2008.106351</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.106351</ArticleId><ArticleId IdType="pmc">PMC2929162</ArticleId><ArticleId IdType="pubmed">19359262</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro-Checa C, Zirkzee EJ, Beaart-van de Voorde LJJ, et al. . Value of multidisciplinary reassessment in Attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from the Leiden NPSLE cohort. Rheumatology (Oxford) 2017;56:1676&#x2013;83. 10.1093/rheumatology/kex019</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex019</ArticleId><ArticleId IdType="pubmed">28339952</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortoluzzi A, Scir&#xe8; CA, Govoni M. Attribution of neuropsychiatric manifestations to systemic lupus erythematosus. Front Med (Lausanne) 2018;5:68. 10.3389/fmed.2018.00068</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2018.00068</ArticleId><ArticleId IdType="pmc">PMC5861139</ArticleId><ArticleId IdType="pubmed">29594125</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanly JG, Kozora E, Beyea SD, et al. . Review: nervous system disease in systemic lupus erythematosus: current status and future directions. Arthritis Rheumatol 2019;71:33&#x2013;42. 10.1002/art.40591</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40591</ArticleId><ArticleId IdType="pubmed">29927108</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojanovich L, Stojanovich R, Kostich V, et al. . Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus 2003;12:3&#x2013;7. 10.1191/0961203303lu251oa</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203303lu251oa</ArticleId><ArticleId IdType="pubmed">12587819</ArticleId></ArticleIdList></Reference><Reference><Citation>Barile-Fabris L, Ariza-Andraca R, Olgu&#xed;n-Ortega L, et al. . Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005;64:620&#x2013;5. 10.1136/ard.2004.025528</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2004.025528</ArticleId><ArticleId IdType="pmc">PMC1755456</ArticleId><ArticleId IdType="pubmed">15769918</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro-Checa C, Zirkzee EJ, Huizinga TW, et al. . Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs 2016;76:459&#x2013;83. 10.1007/s40265-015-0534-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-015-0534-3</ArticleId><ArticleId IdType="pmc">PMC4791452</ArticleId><ArticleId IdType="pubmed">26809245</ArticleId></ArticleIdList></Reference><Reference><Citation>Papachristos DA, Oon S, Hanly JG, et al. . Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum 2021;51:49&#x2013;71. 10.1016/j.semarthrit.2020.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2020.12.004</ArticleId><ArticleId IdType="pubmed">33360230</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolopoulos D, Fanouriakis A, Bertsias G. Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives. Expert Rev Clin Immunol 2021;17:317&#x2013;30. 10.1080/1744666X.2021.1899810</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2021.1899810</ArticleId><ArticleId IdType="pubmed">33682602</ArticleId></ArticleIdList></Reference><Reference><Citation>Govoni M, Hanly JG. The management of neuropsychiatric lupus in the 21st century: still so many unmet needs? Rheumatology (Oxford) 2020;59:v52&#x2013;62. 10.1093/rheumatology/keaa404</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa404</ArticleId><ArticleId IdType="pmc">PMC7719041</ArticleId><ArticleId IdType="pubmed">33280014</ArticleId></ArticleIdList></Reference><Reference><Citation>Zirkzee EJM, Steup-Beekman GM, van der Mast RC, et al. . Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. J Rheumatol 2012;39:2118&#x2013;26. 10.3899/jrheum.120545</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.120545</ArticleId><ArticleId IdType="pubmed">22984275</ArticleId></ArticleIdList></Reference><Reference><Citation>Monahan RC, Fronczek R, Eikenboom J, et al. . Mortality in patients with systemic lupus erythematosus and neuropsychiatric involvement: a retrospective analysis from a tertiary referral center in the Netherlands. Lupus 2020;29:1892&#x2013;901. 10.1177/0961203320963815</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320963815</ArticleId><ArticleId IdType="pmc">PMC7684795</ArticleId><ArticleId IdType="pubmed">33079617</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D, Ginzler E, Goldsmith C, et al. . The development and initial validation of the systemic lupus international collaborating clinics/american College of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363&#x2013;9. 10.1002/art.1780390303</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780390303</ArticleId><ArticleId IdType="pubmed">8607884</ArticleId></ArticleIdList></Reference><Reference><Citation>The American College of rheumatology Nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599&#x2013;608. 10.1002/1529-0131(199904)42:4&lt;599::AID-ANR2&gt;3.0.CO;2-F</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199904)42:4&lt;599::AID-ANR2&gt;3.0.CO;2-F</ArticleId><ArticleId IdType="pubmed">10211873</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JA. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37&#x2013;46. 10.1177/001316446002000104</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/001316446002000104</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourley MF, Austin HA, Scott D, et al. . Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549&#x2013;57. 10.7326/0003-4819-125-7-199610010-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-125-7-199610010-00003</ArticleId><ArticleId IdType="pubmed">8815753</ArticleId></ArticleIdList></Reference><Reference><Citation>Klippel JH. Indications for, and use of, cytotoxic agents in SLE. Baillieres Clin Rheumatol 1998;12:511&#x2013;27. 10.1016/s0950-3579(98)80033-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0950-3579(98)80033-2</ArticleId><ArticleId IdType="pubmed">9890110</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivaldo JF, de Amorim JC, Julio PR, et al. . Definition of npsle: does the acr nomenclature still hold? Front Med (Lausanne) 2018;5:138. 10.3389/fmed.2018.00138</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2018.00138</ArticleId><ArticleId IdType="pmc">PMC5991071</ArticleId><ArticleId IdType="pubmed">29904630</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortoluzzi A, Padovan M, Farina I, et al. . Therapeutic strategies in severe neuropsychiatric systemic lupus erythematosus: experience from a tertiary referral centre. Reumatismo 2012;64:350&#x2013;9. 10.4081/reumatismo.2012.350</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/reumatismo.2012.350</ArticleId><ArticleId IdType="pubmed">23285478</ArticleId></ArticleIdList></Reference><Reference><Citation>Barraclough M, McKie S, Parker B, et al. . Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes. Ann Rheum Dis 2019;78:934&#x2013;40. 10.1136/annrheumdis-2018-214677</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214677</ArticleId><ArticleId IdType="pmc">PMC6585286</ArticleId><ArticleId IdType="pubmed">30979715</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau FA, Vasconcelos C, D&#x2019;Cruz D, et al. . Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121&#x2013;31. 10.1002/art.10461</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10461</ArticleId><ArticleId IdType="pubmed">12209517</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>